Last reviewed · How we verify
Sugammadex vs. Neostigmine
At a glance
| Generic name | Sugammadex vs. Neostigmine |
|---|---|
| Sponsor | Assuta Hospital Systems |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease (PHASE4)
- Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection (PHASE4)
- Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial (PHASE3)
- Sugammadex vs Neostigmine Reversal in Pediatric Appendectomy (PHASE4)
- Sugammadex vs Neostigmine/Glycopyrrolate on Urinary Retention After Spine Surgery (PHASE4)
- Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications (PHASE4)
- Low Dose of Sugammadex vs Neostigmine and Glycopyrrolate for the Reversal of Rocuronium (PHASE4)
- Remifentanil in Deep vs Moderate Neuromuscular Blocks During Surgical Pleth Index-guided Anesthesia for Laparoscopic Herniorrhaphy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sugammadex vs. Neostigmine CI brief — competitive landscape report
- Sugammadex vs. Neostigmine updates RSS · CI watch RSS
- Assuta Hospital Systems portfolio CI